NCT04720313 - NXC-201 (formerly HBI0101) Multiple Myeloma | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Dose Escalation and Safety

Interventions

DRUG

NXC-201 (formerly HBI0101)

NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.

Trial Locations (1)

91120

Hadassah University Hospital, Jerusalem